SlideShare una empresa de Scribd logo
1 de 19
M.V. LOMONOSOV MOSCOW STATE UNIVERSITY  FACULTY OF BASIC MEDICINE   COMPARISON OF  POLY- CHEMOTHERAPY (CVD regimen) & THE SAME CHEMOTHERAPY (CT) PLUS INTERFERON-α2a IN METASTATIC MELANOMA Student: Dr. Kyaw Thura Zaw  Scientific Supervisor :  Prof. Dr. Lev Demidov  N.N. BLOKHIN CANCER RESEARCH CENTRE  Moscow ,2010
INTRODUCTION ,[object Object],[object Object]
[object Object]
Epidemiology ,[object Object],[object Object]
Race Melanoma is more common in whites than in blacks and Asians. The rate of melanoma in blacks is estimated to be  1/120  that of whites.  Sex Melanoma is slightly more common in men than women (1.2:1). Melanoma is the 5th most common malignancy in men and the 6th most common malignancy in women, accounting for 5% and 4% of all new cancer case. respectively.
Risk Factors  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
A=Asymmetry  B=Border (irregular) C= Color D= Diameter ABCD Properties of Radial Melanomas
A 1.5-cm melanoma with characteristic  asymmetry, irregular borders, and color variation.
Factors Predicting the Outcome of Response of Treatment  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
AIM OF STUDY To Study and Compare the  Poly-chemotherapy (CVD regimen) & the Same Chemotherapy(CT)plus Interferon  α - 2 a in Metastatic Melanoma.
Objectives  of Study ,[object Object],[object Object],[object Object]
Materials and Methods
Patient’s Characteristics CVD P  CVD+IFN P Age , median (min-max) 55 (35-65) P<0.01 52(30-65) P<0.10 ECOG PS  0 2 P=1.00 2 P=1.00 1 3 P>0.10 6 P>0.25 2 10 P>0.10 7 P>0.30 Metastatic sites Skin 4 P>0.25 6 P>0.10 Lymph node 10 P>0.70 9 P>0.25 Lungs 9 P=1.00 9 P=1.00 Liver 9 P>0.10 6 P>0.10 Other 3 P>0.10 0 P>0.20 Number of Metastases 1 1 P>0.10 4 P>0.10 2 8 P>0.70 7 P>0.70 3 6 P>0.25 4 P>0.25
Treatment Schedules ,[object Object],[object Object]
Response of Therapy
[object Object],[object Object],[object Object],COMPARISON BETWEEN THE RESULT OF CVD AND CVD+IFN
Overall survival. Heavy line represents CVD + IFN group; Fine line represents CVD group ; No. of death /Total No. Average survival Survival Median CVD+IFN 8/15 13.51(9.7;17.3) 12.0(9.9;14.1) CVD 7/15 10.75(9.1;12.4) 12.0(7.8;16.2)
  CONCLUSIONS ,[object Object],[object Object],[object Object]
 

Más contenido relacionado

La actualidad más candente

Multiple myeloma and plasmacytoma
Multiple myeloma and plasmacytomaMultiple myeloma and plasmacytoma
Multiple myeloma and plasmacytomaNilesh Kucha
 
Current and emerging biomarkers of breast cancer
Current and emerging biomarkers of breast cancerCurrent and emerging biomarkers of breast cancer
Current and emerging biomarkers of breast cancerRD-Fasiha Ahsan
 
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...Health Sciences North | Horizon Santé Nord
 
Crpc the paradigm of sequence
Crpc  the paradigm of sequenceCrpc  the paradigm of sequence
Crpc the paradigm of sequenceMohamed Abdulla
 
NEOPLASIA: CARCINOGENESIS
NEOPLASIA: CARCINOGENESISNEOPLASIA: CARCINOGENESIS
NEOPLASIA: CARCINOGENESISDr. Roopam Jain
 
General principles in chemotherapy of cancer
General principles in chemotherapy of cancerGeneral principles in chemotherapy of cancer
General principles in chemotherapy of cancerKLE COLLEGE OF PHARMACY
 
Leptomeningeal mets in solid tumors
Leptomeningeal mets in solid tumorsLeptomeningeal mets in solid tumors
Leptomeningeal mets in solid tumorsJoydeep Ghosh
 
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Fight Colorectal Cancer
 
Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...
Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...
Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...Prof. Eric Raymond Oncologie Medicale
 
Chapter 5 hereditary cancer syndrome next generation
Chapter 5 hereditary cancer syndrome next generationChapter 5 hereditary cancer syndrome next generation
Chapter 5 hereditary cancer syndrome next generationNilesh Kucha
 
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...OSUCCC - James
 
Indolent Non-Hodgkin’s Lymphoma Sharman slides
Indolent Non-Hodgkin’s Lymphoma Sharman slidesIndolent Non-Hodgkin’s Lymphoma Sharman slides
Indolent Non-Hodgkin’s Lymphoma Sharman slidesСергей Сердюк
 
A 2020 Renal Cancer update
 A 2020 Renal Cancer update   A 2020 Renal Cancer update
A 2020 Renal Cancer update malcolmbrigden
 
Chapter 38 role of surgery in cancer prevention
Chapter 38 role of surgery in cancer preventionChapter 38 role of surgery in cancer prevention
Chapter 38 role of surgery in cancer preventionNilesh Kucha
 

La actualidad más candente (20)

CRPC
CRPCCRPC
CRPC
 
Multiple myeloma and plasmacytoma
Multiple myeloma and plasmacytomaMultiple myeloma and plasmacytoma
Multiple myeloma and plasmacytoma
 
Cancer biomarker
Cancer biomarkerCancer biomarker
Cancer biomarker
 
Current and emerging biomarkers of breast cancer
Current and emerging biomarkers of breast cancerCurrent and emerging biomarkers of breast cancer
Current and emerging biomarkers of breast cancer
 
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...
 
Basic principles of cancer therapy
Basic principles of cancer therapyBasic principles of cancer therapy
Basic principles of cancer therapy
 
Crpc the paradigm of sequence
Crpc  the paradigm of sequenceCrpc  the paradigm of sequence
Crpc the paradigm of sequence
 
NEOPLASIA: CARCINOGENESIS
NEOPLASIA: CARCINOGENESISNEOPLASIA: CARCINOGENESIS
NEOPLASIA: CARCINOGENESIS
 
Cancer biology
Cancer biologyCancer biology
Cancer biology
 
General principles in chemotherapy of cancer
General principles in chemotherapy of cancerGeneral principles in chemotherapy of cancer
General principles in chemotherapy of cancer
 
IHC in breast CA
IHC in breast CAIHC in breast CA
IHC in breast CA
 
Leptomeningeal mets in solid tumors
Leptomeningeal mets in solid tumorsLeptomeningeal mets in solid tumors
Leptomeningeal mets in solid tumors
 
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
 
Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...
Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...
Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...
 
Chapter 5 hereditary cancer syndrome next generation
Chapter 5 hereditary cancer syndrome next generationChapter 5 hereditary cancer syndrome next generation
Chapter 5 hereditary cancer syndrome next generation
 
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
 
Indolent Non-Hodgkin’s Lymphoma Sharman slides
Indolent Non-Hodgkin’s Lymphoma Sharman slidesIndolent Non-Hodgkin’s Lymphoma Sharman slides
Indolent Non-Hodgkin’s Lymphoma Sharman slides
 
Genomics and Cancer
Genomics and CancerGenomics and Cancer
Genomics and Cancer
 
A 2020 Renal Cancer update
 A 2020 Renal Cancer update   A 2020 Renal Cancer update
A 2020 Renal Cancer update
 
Chapter 38 role of surgery in cancer prevention
Chapter 38 role of surgery in cancer preventionChapter 38 role of surgery in cancer prevention
Chapter 38 role of surgery in cancer prevention
 

Destacado

Personas with Personality
Personas with PersonalityPersonas with Personality
Personas with PersonalityBrightEdge
 
PPC Attribution: A Portent & Hanapin Webinar
PPC Attribution: A Portent & Hanapin WebinarPPC Attribution: A Portent & Hanapin Webinar
PPC Attribution: A Portent & Hanapin WebinarBrightEdge
 
Tanl power point
Tanl power pointTanl power point
Tanl power pointzawhtet1984
 

Destacado (7)

Aung citt nyein
Aung citt nyeinAung citt nyein
Aung citt nyein
 
Sithu ko
Sithu koSithu ko
Sithu ko
 
Zaw htet
Zaw htetZaw htet
Zaw htet
 
Personas with Personality
Personas with PersonalityPersonas with Personality
Personas with Personality
 
PPC Attribution: A Portent & Hanapin Webinar
PPC Attribution: A Portent & Hanapin WebinarPPC Attribution: A Portent & Hanapin Webinar
PPC Attribution: A Portent & Hanapin Webinar
 
Aung thiha soe
Aung thiha soeAung thiha soe
Aung thiha soe
 
Tanl power point
Tanl power pointTanl power point
Tanl power point
 

Similar a Kyaw thura zaw

Newly Diagnosed Myeloma
Newly Diagnosed MyelomaNewly Diagnosed Myeloma
Newly Diagnosed Myelomaspa718
 
Metastatic renal cell carcinoma
Metastatic renal cell carcinomaMetastatic renal cell carcinoma
Metastatic renal cell carcinomaHarshaR35
 
Renal Cell Carcinoma Diagnosis And Management
Renal Cell Carcinoma Diagnosis And ManagementRenal Cell Carcinoma Diagnosis And Management
Renal Cell Carcinoma Diagnosis And ManagementRHMBONCO
 
Vorinostat Case Study
Vorinostat Case StudyVorinostat Case Study
Vorinostat Case StudyAshley Jean
 
Immunotherapies in management of HCC
Immunotherapies in management of HCCImmunotherapies in management of HCC
Immunotherapies in management of HCCAhmed Elmoughazy
 
METASTATC COLORECTAL CANCER IN 2017
METASTATC COLORECTAL CANCER IN 2017METASTATC COLORECTAL CANCER IN 2017
METASTATC COLORECTAL CANCER IN 2017Mohamed Abdulla
 
Hepatoblastoma- Investigations and management
Hepatoblastoma- Investigations and managementHepatoblastoma- Investigations and management
Hepatoblastoma- Investigations and managementARJUN MANDADE
 
apmlseminarmine
apmlseminarmineapmlseminarmine
apmlseminarmineicdlab
 
BP JCSO RCC Supplement_FINAL
BP JCSO RCC Supplement_FINALBP JCSO RCC Supplement_FINAL
BP JCSO RCC Supplement_FINALDean Celia
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinomaspa718
 
Immunotherapy and Heme/Onc Emergencies for Emergency Medicine
Immunotherapy and Heme/Onc Emergencies for Emergency MedicineImmunotherapy and Heme/Onc Emergencies for Emergency Medicine
Immunotherapy and Heme/Onc Emergencies for Emergency MedicineDavid Marcus
 
Slide deck updates on cml (1)
Slide deck updates on cml (1)Slide deck updates on cml (1)
Slide deck updates on cml (1)madurai
 
Chemotherapy in rhabdomyosarcoma
Chemotherapy in rhabdomyosarcomaChemotherapy in rhabdomyosarcoma
Chemotherapy in rhabdomyosarcomaSameer Rastogi
 
Acute Promyelocytic Leukaemia
Acute Promyelocytic LeukaemiaAcute Promyelocytic Leukaemia
Acute Promyelocytic LeukaemiaDr. Renesha Islam
 

Similar a Kyaw thura zaw (20)

Newly Diagnosed Myeloma
Newly Diagnosed MyelomaNewly Diagnosed Myeloma
Newly Diagnosed Myeloma
 
Metastatic renal cell carcinoma
Metastatic renal cell carcinomaMetastatic renal cell carcinoma
Metastatic renal cell carcinoma
 
Renal Cell Carcinoma Diagnosis And Management
Renal Cell Carcinoma Diagnosis And ManagementRenal Cell Carcinoma Diagnosis And Management
Renal Cell Carcinoma Diagnosis And Management
 
Vorinostat Case Study
Vorinostat Case StudyVorinostat Case Study
Vorinostat Case Study
 
Immunotherapies in management of HCC
Immunotherapies in management of HCCImmunotherapies in management of HCC
Immunotherapies in management of HCC
 
METASTATC COLORECTAL CANCER IN 2017
METASTATC COLORECTAL CANCER IN 2017METASTATC COLORECTAL CANCER IN 2017
METASTATC COLORECTAL CANCER IN 2017
 
Hepatoblastoma- Investigations and management
Hepatoblastoma- Investigations and managementHepatoblastoma- Investigations and management
Hepatoblastoma- Investigations and management
 
apmlseminarmine
apmlseminarmineapmlseminarmine
apmlseminarmine
 
BP JCSO RCC Supplement_FINAL
BP JCSO RCC Supplement_FINALBP JCSO RCC Supplement_FINAL
BP JCSO RCC Supplement_FINAL
 
Erbitux
ErbituxErbitux
Erbitux
 
Cancer chemotherapy part i
Cancer chemotherapy part iCancer chemotherapy part i
Cancer chemotherapy part i
 
Cancer chemotherapy part I
Cancer chemotherapy part ICancer chemotherapy part I
Cancer chemotherapy part I
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinoma
 
Prostate cancer
Prostate cancer Prostate cancer
Prostate cancer
 
Advances in Melanoma Oncology - Mike Atkins, MD
Advances in Melanoma Oncology - Mike Atkins, MDAdvances in Melanoma Oncology - Mike Atkins, MD
Advances in Melanoma Oncology - Mike Atkins, MD
 
Immunotherapy and Heme/Onc Emergencies for Emergency Medicine
Immunotherapy and Heme/Onc Emergencies for Emergency MedicineImmunotherapy and Heme/Onc Emergencies for Emergency Medicine
Immunotherapy and Heme/Onc Emergencies for Emergency Medicine
 
Slide deck updates on cml (1)
Slide deck updates on cml (1)Slide deck updates on cml (1)
Slide deck updates on cml (1)
 
Chemotherapy in rhabdomyosarcoma
Chemotherapy in rhabdomyosarcomaChemotherapy in rhabdomyosarcoma
Chemotherapy in rhabdomyosarcoma
 
Tumour marker
Tumour markerTumour marker
Tumour marker
 
Acute Promyelocytic Leukaemia
Acute Promyelocytic LeukaemiaAcute Promyelocytic Leukaemia
Acute Promyelocytic Leukaemia
 

Más de zawhtet1984

Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)zawhtet1984
 
Powerpoint presentation by dr sathiha
Powerpoint presentation by dr sathihaPowerpoint presentation by dr sathiha
Powerpoint presentation by dr sathihazawhtet1984
 
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Aung myo zaw(nutrition in  preterm and congenital hypotrophy)Aung myo zaw(nutrition in  preterm and congenital hypotrophy)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)zawhtet1984
 

Más de zawhtet1984 (6)

Yehlaingbwar
YehlaingbwarYehlaingbwar
Yehlaingbwar
 
Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)
 
Powerpoint presentation by dr sathiha
Powerpoint presentation by dr sathihaPowerpoint presentation by dr sathiha
Powerpoint presentation by dr sathiha
 
Khant zaw aung
Khant zaw aungKhant zaw aung
Khant zaw aung
 
Chan myae htut
Chan myae htutChan myae htut
Chan myae htut
 
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Aung myo zaw(nutrition in  preterm and congenital hypotrophy)Aung myo zaw(nutrition in  preterm and congenital hypotrophy)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
 

Último

Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin ClassesCeline George
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDThiyagu K
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxVishalSingh1417
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingTechSoup
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityGeoBlogs
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104misteraugie
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterMateoGardella
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsTechSoup
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxVishalSingh1417
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeThiyagu K
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docxPoojaSen20
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfJayanti Pande
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfChris Hunter
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...EduSkills OECD
 

Último (20)

Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SD
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch Letter
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docx
 
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 

Kyaw thura zaw

  • 1. M.V. LOMONOSOV MOSCOW STATE UNIVERSITY FACULTY OF BASIC MEDICINE   COMPARISON OF POLY- CHEMOTHERAPY (CVD regimen) & THE SAME CHEMOTHERAPY (CT) PLUS INTERFERON-α2a IN METASTATIC MELANOMA Student: Dr. Kyaw Thura Zaw Scientific Supervisor : Prof. Dr. Lev Demidov N.N. BLOKHIN CANCER RESEARCH CENTRE Moscow ,2010
  • 2.
  • 3.
  • 4.
  • 5. Race Melanoma is more common in whites than in blacks and Asians. The rate of melanoma in blacks is estimated to be 1/120 that of whites. Sex Melanoma is slightly more common in men than women (1.2:1). Melanoma is the 5th most common malignancy in men and the 6th most common malignancy in women, accounting for 5% and 4% of all new cancer case. respectively.
  • 6.
  • 7. A=Asymmetry B=Border (irregular) C= Color D= Diameter ABCD Properties of Radial Melanomas
  • 8. A 1.5-cm melanoma with characteristic asymmetry, irregular borders, and color variation.
  • 9.
  • 10. AIM OF STUDY To Study and Compare the Poly-chemotherapy (CVD regimen) & the Same Chemotherapy(CT)plus Interferon α - 2 a in Metastatic Melanoma.
  • 11.
  • 13. Patient’s Characteristics CVD P CVD+IFN P Age , median (min-max) 55 (35-65) P<0.01 52(30-65) P<0.10 ECOG PS 0 2 P=1.00 2 P=1.00 1 3 P>0.10 6 P>0.25 2 10 P>0.10 7 P>0.30 Metastatic sites Skin 4 P>0.25 6 P>0.10 Lymph node 10 P>0.70 9 P>0.25 Lungs 9 P=1.00 9 P=1.00 Liver 9 P>0.10 6 P>0.10 Other 3 P>0.10 0 P>0.20 Number of Metastases 1 1 P>0.10 4 P>0.10 2 8 P>0.70 7 P>0.70 3 6 P>0.25 4 P>0.25
  • 14.
  • 16.
  • 17. Overall survival. Heavy line represents CVD + IFN group; Fine line represents CVD group ; No. of death /Total No. Average survival Survival Median CVD+IFN 8/15 13.51(9.7;17.3) 12.0(9.9;14.1) CVD 7/15 10.75(9.1;12.4) 12.0(7.8;16.2)
  • 18.
  • 19.